Baird analyst Brian Skorney lowered the firm’s price target on Biogen to $316 from $333 and keeps an Outperform rating on the shares. The firm said 4Q23 earnings were a bit disappointing, with a miss on the top and bottom lines and weaker-than-expected Leqembi, Skyclarys and Spinraza sales, the most important franchises for the company right now.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BIIB:
- Biogen (NASDAQ:BIIB) Plunges as Earnings Disappoint
- Options Volatility and Implied Earnings Moves Today, February 13, 2024
- Notable companies reporting before tomorrow’s open
- Biogen receives EC approval for Skyclarys
- Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
